Insight Molecular Diagnostics (IMDX) Earnings Analysis

Insight Molecular Diagnostics (IMDX) next reports earnings on 2026-08-10, consensus EPS -0.24 USD. Last quarter (2026-03-26) it missed with EPS -0.27 USD vs -0.2375 USD est (-13.7%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -3.30.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does IMDX next report earnings?

Next earnings date2026-08-10
Consensus EPS estimate-0.24 USD
Revenue estimate0.00B

IMDX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-26-0.27 USD-0.2375 USD-13.7%Miss
2025-11-10-0.34 USD-0.24 USD-41.7%Miss
2025-08-11-0.3 USD-0.23 USD-30.4%Miss
2025-05-12-0.26 USD-0.24 USD-8.3%Miss
2025-03-240.48 USD-0.43 USD+211.6%Beat
2024-08-08-0.36 USD-0.56 USD+35.7%Beat

Beat rate: 2/6 (33%) over reported quarters with consensus data.

IMDX valuation and analyst view

Trailing P/E-3.30
Trailing EPS-1.38593 USD
Price / book-16.11
Dividend yield0.00%
Market cap0.14B
Analyst consensusBuy (7 buy / 4 hold / 0 sell)
Avg price target10.5 USD

Related research pages

Frequently asked questions

When is Insight Molecular Diagnostics (IMDX)'s next earnings date?

Insight Molecular Diagnostics is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.24 USD and revenue estimate of 0.00B.

Did IMDX beat earnings last quarter?

In its 2026-03-26 report, IMDX posted EPS of -0.27 USD versus a -0.2375 USD estimate — a miss of 13.7%.

What is IMDX's earnings track record?

Over the last 6 reported quarters with consensus data, IMDX beat estimates 2 times (33%).

What is IMDX's current P/E ratio and EPS?

IMDX trades at a trailing P/E of -3.30 on trailing EPS of -1.3859323850632985 USD.

What do analysts rate IMDX?

Analyst consensus is "Buy" across 11 ratings (0 strong buy, 7 buy, 4 hold, 0 sell, 0 strong sell). Average 12-month price target: 10.5 USD.